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Five inherited human disorders affecting skeletal muscle contraction have been traced to
mutations in the gene encoding the voltage-gated sodium channel Nav1.4.The main symp-
toms of these disorders are myotonia or periodic paralysis caused by changes in skeletal
muscle ﬁber excitability. Symptoms of these disorders vary from mild or latent disease to
incapacitating or even death in severe cases. As new human sodium channel mutations
corresponding to disease states become discovered, the importance of understanding the
role of the sodium channel in skeletal muscle function and disease state grows.
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INTRODUCTION
Voltage-gated sodium channels are essential in the generation and
propagation of action potentials (APs) in excitable tissues such as
muscle,heart, andnerve. Proper activity of these channels is crucial
to the initiation of APswhichultimately lead tomuscle contraction
or neuronal ﬁring. The necessity of Na+ channels is better empha-
sized by the existence of human inherited skeletalmuscle disorders
caused by mutations in the Na+ channel Nav1.4 which is specif-
ically expressed in skeletal muscle. Mutations in the SCN4A gene
encoding the human skeletal muscle Nav1.4 channel cause ﬁve dif-
ferent skeletal muscle disorders: potassium-aggravated myotonia
(PAM), paramyotonia congenita (PMC), hyperkalemic periodic
paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP),
and a form of congenital myasthenic syndrome (CMS). This
review focuses on the role of Nav1.4 channel in skeletal muscle and
the complex clinical symptoms of these disorders. Also the most
recent ﬁndings of new Nav1.4 mutations causing a lethal form of
myotonia will be discussed as well as treatment options for such
disorders. An overview of skeletal muscle physiology is provided
in order to illustrate the signiﬁcance of ion channels within the
skeletal muscle and their critical roles in muscle function.
SKELETAL MUSCLE PHYSIOLOGY
Skeletal muscles have complex structures working in concert to
provide the appropriate response to nerve impulse and metabolic
processes. Specialized compartments within skeletal muscle ﬁbers
such as neuromuscular junctions, sarcolemmamembrane, traverse
tubules, and the sarcoplasmic reticulum (SR) provide the mechan-
ical architecture required for the excitation–contraction coupling
mechanism to take place.
At the neuromuscular junction, motoneuron activity is trans-
ferred to skeletalmuscle generating an acetylcholine (ACh) depen-
dent endplate potential. ACh is released from the nerve terminal
and binds to nicotinic acetylcholine receptors (AChR). A large
enough endplate potential can induce a sarcolemmalAP that prop-
agates from the endplate to the tendon and through the transverse
tubular (T-tubules) system which is mediated by the opening of
the voltage-gated Nav1.4 Na+ channels. Na+ channels quickly
inactivate and the depolarized potential enables the opening of
delayed rectiﬁer K+ channels which mediate outward K+ current
during the repolarization stage of the muscle AP (Jurkat-Rott and
Lehmann-Horn, 2005). High chloride channel (Cl−) conductance
then takes over to enforce the ﬁnal repolarization or to reduce the
afterdepolarization of the skeletal muscle ﬁber. This afterdepolar-
ization is skeletal muscle AP speciﬁc and consists of an early and
late phase mediated by different ionic currents (Jurkat-Rott et al.,
2006). The early phase is caused by the spread of the depolar-
ization spike in the T-tubules while the late phase is considered
to be caused by accumulation of K+ ions in the T-tubules which
increases with frequency and duration of repetitive APs (Almers,
1980). Inward chloride conductance in the T-tubular system alle-
viates some of the depolarization caused by the extracellular K+
accumulation by producing a more negative membrane poten-
tial than K+ equilibrium, which stimulates inward potassium ﬂux
(Jurkat-Rott et al., 2006).
The contraction of the muscle occurs as a result of Ca2+ release
from the SR which binds to troponin (a calcium binding protein
which is part of the thin ﬁlaments necessary to produce mus-
cle contraction) enabling ﬁlament sliding and contraction. The
process, which allows Ca2+ release, is initiated by voltage changes
of the AP. These changes will target in part the voltage sensor of
the voltage-gated Cav1.1 Ca2+ channel (Dihydropyridine recep-
tor or DHPR) leading to channel conformation rearrangements.
The DHPR is believed to physically interact with a calcium release
channel of the SR the ryanodine receptor (RYR) which releases
calcium stores from the SR allowing calcium to bind to troponin
(Rios et al., 1991). When the AP is over, the RYR close and Ca2+ is
transported back to the SR via Ca2+ATPases (SERCA).
SKELETAL MUSCLE Na+ CHANNEL STRUCTURE AND GATING
Voltage-gated sodium channels are large integral membrane pro-
teins expressed densely at the neuromuscular junctions where they
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selectively conduct sodium ions into the muscle ﬁbers in physio-
logical conditions. The Nav1.4 channel is composed of a 260-kDa
α-subunitwhich consists of four homologous domains (I–IV), and
each domain has six transmembrane segments (S1–S6; Figure 1;
Noda et al., 1984; George et al., 1992a,b). The Nav1.4 channels
complex structure formed at the membrane incorporates several
important gating domains facilitating the channel’ three different
gating states: resting (closed), activated (open), and inactivated
(closed). When a voltage change occurs at cell surface, voltage
sensing domains at the S4 segments sense this change and shift
their conformation within the membrane relaying this change to
the channels internal activation gate and opening it in a very fast
manner. Within milliseconds of this fast activation, a ball and
chain gate located at the intracellular loop between domains III
and IV blocks the intracellular pore of the channel allowing the
channel to quickly inactivate (Armstrong andBezanilla, 1977;West
et al., 1992). This fast inactivation process is voltage dependent and
occurs at a greater extent and for a longer duration when mem-
brane potentials are more depolarized. Before the channel can be
opened again, the internal gate must close and deactivate and the
ball and chain gate must be released, this process is called recovery
from fast inactivation. Recovery from fast inactivation requires a
hyperpolarized membrane potential to last several milliseconds.
In addition to fast inactivation, slow inactivation occurs when the
channel has been activated repeatedly during exercise, this pre-
vents the channel from being available for further activation for
hundreds of milliseconds to seconds. The slow (on the order of
seconds to minutes) inactivation process enables the muscle to
recover more quickly from exercise.
SKELETAL MUSCLE PATHOPHYSIOLOGY
Over 40 Nav1.4 channel mutations leading to disease states have
been found throughout each domain and segment of this channel
FIGURE 1 | Basic structure of the voltage-gated sodium channel.
Structural arrangement of the Nav1.4 channel α-subunit which is organized
into four homologous domains (I to IV) and possesses six transmembrane
segments (S1–S6), a pore-forming loop located between S5 and S6
segments, and cytosolic NH3 and COOH termini. The schematic diagram of
the Nav1.4 channel shows the location of the mutations associated with
hyperkalemic periodic paralysis (HyperPP), hypokalemic periodic paralysis
(HypoPP), normokalemic periodic paralysis (NormoPP), paramyotonia
congenita (PMC), potassium-aggravated myotonia (PAM), cold-aggravated
myotonia (CAM), and congenital myasthenic syndrome (CMS).
(Figure 1 and Table 1). These Nav1.4 mutations produce changes
that interferewith channel kinetics or function,producing changes
in the micro or macroscopic electrophysiological properties of
the skeletal muscle ﬁbers thus underlying muscle hyperexcitability
or inexcitability. Skeletal muscle Na+ channel disorders are non-
dystrophic and consist of myotonia which presents as an increased
muscular activity causing muscle stiffness, and periodic paralysis
which presents as a decrease in muscle activity causing transient
weakness or paralysis of the muscle.
MYOTONIA
A common feature of myotonia is delayed relaxation of the muscle
after voluntary contraction or mechanical stimulation, electro-
physiologically characterized by highly organized repetitive elec-
trical activity of the muscle ﬁbers. Non-dystrophic myotonias can
be caused by mutations in the Nav1.4 sodium channel which
increases its function or the ClC-1 chloride channel decreas-
ing channel function (Trip et al., 2008). Mutations causing up-
regulation of the Nav1.4 sodium channel can cause PMC or PAM
depending on the type of mutation and its functional effect on this
channel. Both PMC and PAM cause repetitive APs and increase
activity of the muscle leading to myotonia or muscle rigidity.
POTASSIUM-AGGRAVATED MYOTONIA
Potassium-aggravated myotonia includes atypical myotonia con-
genita,moderate myotonia,myotonia ﬂuctuans,myotonia perma-
nens, acetazolamide-responsive myotonia, and painful myotonia
which have overlapping clinical features. The prevalence of PAM is
estimated at ∼1:400,000 (Lehmann-Horn et al., 2004). Myotonia
ﬂuctuans and moderate PAM patients exhibit stiffness during the
ﬁrst contractions after rest and thus complain that they are par-
ticularly stiff after rest. Upon further contractions, their muscles
begin to warm up improving the initial stiffness, this occurrence is
termed the warm-up phenomenon. However, other PAM patients
become stiff within 10–30min of strenuous work which may last
for several hours (Lehmann-Horn et al., 2004).
Potassium-aggravated myotonia is exacerbated by potassium
ingestion (but not cold temperatures) because increased K+ inges-
tion causes cellular depolarization (George, 2005). Also unlike
other myotonias PAM does not present with any major weakness.
Eight Nav1.4 mutations causing PAM have been found in
humans: V445M, S804F, I1160V, G1306A/V/E, V1458F, F1473S,
and V1589M (McClatchey et al., 1992; Lehmann-Horn et al.,
1993; Lerche et al., 1993; Mitrovic et al., 1994, 1995; Ptácek et al.,
1994b; Richmond et al., 1997; Fleischhauer et al., 1998; Green
et al., 1998; Hayward et al., 1999; Takahashi and Cannon, 1999;
Wang et al., 1999; Groome et al., 2005). The clinical phenotypes of
I1160V andV1589M mutations present as atypical myotonia con-
genita,G1306A presentsmyotonia ﬂuctuans, andG1306E presents
myotonia permanens. Most of these PAM mutations are situated
in the interface between the cytosol and the membrane which is
the location of the inactivation gate. An example of this is with
the G1306 residue that is thought to act as the hinge for the inacti-
vation gate. The more different the substituting mutation is from
glycine the more severe are the clinical symptoms ranging from
myotonia ﬂuctuans (a benign form of myotonia) to myotonia
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Table 1 | Disorders of the skeletal muscle and the associated Nav1.4
mutations.
Mutation Location Phenotype References
I141V IS1 SCM Petitprez et al. (2008)
R222W ISIV HypoPP Park and Kim (2010)
R225W ISIV SCM Lee et al. (2009)
L266V IS5 PMC/CAM Wu et al. (2001)
Q270K IS5 PAM Carle et al. (2009)
V445M IS6 PAM Wang et al. (1999)
R669H IIS4-1 HypoPP Struyk et al. (2000),
Kuzmenkin et al. (2002)
R672H IIS4-2 HypoPP Kuzmenkin et al. (2002)
R672G IIS4-2 HypoPP Kuzmenkin et al. (2002)
R672S IIS4-2 HypoPP Bendahhou et al. (2001)
R672C IIS4-2 HypoPP Kim et al. (2004)
R675G IIS4-3 NormoPP Vicart et al. (2004)
R675Q IIS4-3 NormoPP Vicart et al. (2004)
R675W IIS4-3 NormoPP Vicart et al. (2004)
L689I IIS4S5 HyperPP Bendahhou et al. (2002)
I693T IIS4S5 HyperPP Plassart-Schiess et al.
(1998)
T704M IIS4S5 HyperPP Cannon and Strittmatter
(1993), Cummins et al.
(1993), Yang et al. (1994),
Bendahhou et al. (1999b)
V781I IIS6 HyperPP? Baquero et al. (1995),
Green et al. (1997)
A799S IIS6 SCM/SNEL Lion-Francois et al. (2010),
Simkin et al. (2011)
S804F IIS6 PAM McClatchey et al. (1992),
Green et al. (1998)
R1132Q IIIS4 HypoPP Carle et al. (2006)
R1135H IIIS4 HypoPP Matthews et al. (2009)
A1152D IIIS4S5 PMC Bouhours et al. (2005)
A1156T IIIS4S5 PMC/HyperPP McClatchey et al. (1992),
Yang et al. (1994), Hayward
et al. (1999)
P1158S IIIS4S5 HypoPP/SCM Sugiura et al. (2003)
I1160V IIIS4S5 PAM Richmond et al. (1997)
V1293I IIIS6 PMC Green et al. (1998)
N1297K III–IV CAM Gay et al. (2008)
G1306A III–IV PAM Mitrovic et al. (1995),
Groome et al. (2005)
G1306V III–IV PAM Mitrovic et al. (1995),
Groome et al. (2005)
G1306E III–IV PAM/PMC Mitrovic et al. (1995),
Groome et al. (2005)
T1313M III–IV PMC Yang et al. (1994), Hayward
et al. (1997)
T1313A III–IV PMC Bouhours et al. (2004)
M1360V IVS1 PMC/HyperPP Wagner et al. (1997)
I1363T IVS1 PMC Miller et al. (2004)
M1370V IVS1 PMC Okuda et al. (2001)
L1433R IVS3 PMC Yang et al. (1994)
(Continued)
Table 1 | Continued
Mutation Location Phenotype References
L1436P IVS3 PMC/CAM Matthews et al. (2008),
Bissay et al. (2011)
V1442E IVS4 CMS Tsujino et al. (2003)
R1448C IVS4-1 PMC Chahine et al. (1994),
Yang et al. (1994)
R1448H IVS4-1 PMC Chahine et al. (1994),
Yang et al. (1994)
R1448P IVS4-1 PMC Lerche et al. (1996),
Featherstone et al. (1998)
R1448S IVS4-1 PMC Bendahhou et al. (1999a)
G1456E IVS4 PMC Sasaki et al. (1999)
V1458F IVS4 PAM Lehmann-Horn et al.
(1993)
F1473S IVS4S5 PAM Fleischhauer et al. (1998)
M1476I IVS4S5 SCM Rossignol et al. (2007)
A1481D IVS4S5 CAM Schoser et al. (2007)
I1490L/M1493I IVS5 HyperPP/SCM Bendahhou et al. (2000)
I1495F IVS5 HyperPP Bendahhou et al. (1999b)
V1589M IVS6 PAM Mitrovic et al. (1994),
Hayward et al. (1999)
M1592V IVS6 HyperPP Cannon and Strittmatter
(1993), Rojas et al. (1999)
Q1633E C-term PAM Kubota et al. (2009)
E1702K C-term PMC Miller et al. (2004)
F1705I C-term PMC Wu et al. (2005)
NormoPP, normokalemic periodic paralysis; HypoPP, hypokalemic periodic paral-
ysis; HyperPP, hyperkalemic periodic paralysis; PMC, paramyotonia congenita;
PAM, potassium-aggravated myotonia; CAM, cold-aggravated myotonia; SCM,
sodium channel myotonia; SNEL, severe neonatal episodic laryngospasm; CMS,
congenital myasthenic syndrome.
permanens a severe myotonia (Lerche et al., 1993; Mitrovic et al.,
1994).
Nav1.4 channel kinetics are altered by these mutations in such
a way that the channel open probability is increased thus channel
activity is up-regulated. With some of these PAM mutations, the
rate of fast inactivation is slowed which allows the channels to stay
open for a prolonged amount of time. However, the rate of recov-
ery from inactivation is not found to be increased but deactivation
is found to be slow for most of these PAM mutations. Most of
these mutations have been reported to increase the size of the per-
sistent Na+ current two to fourfold. The increase in this inward
Na+ current generates after-depolarizations across the T-tubules
and decreases the threshold required for AP generation conse-
quently triggering repetitive AP and muscle contraction (Adrian
and Marshall, 1976).
PARAMYOTONIA CONGENITA
Paramyotonia congenita is different from PAM in that mus-
cle stiffness is usually followed by ﬂaccid weakness or paralysis
(Lehmann-Horn et al., 2004). This form of myotonia is exac-
erbated by cold temperatures and muscle stiffness is increased
with continued activity which is considered a paradoxical effect
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(Jackson et al., 1994;Vicart et al., 2005). Cold inducedmyotonia or
weakness can last for several hours even if muscles are immediately
re-warmed after short exposure to cold. The effect of temperature
on cell excitability in PMC has been suggested to be a result of
normal slowing of channel kinetics with cooling, and was not
attributed to a consequence of altered Nav1.4 temperature sensi-
tivity (Lerche et al., 1996; Fleischhauer et al., 1998;Dice et al., 2004;
Webb and Cannon, 2008). In some cases of PMC, patients are sen-
sitive to serum potassium levels, however, unlike with PAM these
patients exhibit weakness provoked by a hypokalemic challenge
(Ptácek et al., 1993b; Lehmann-Horn et al., 2004). The main char-
acteristic of PMC is both cold exacerbated myotonia and muscle
weakness. This suggests that the PMC mutations under different
physiological conditions lead to an increased Na+ channel activity
causingmyotonia or inactivationof the channelwithparalysis. The
prevalence of PMC is∼1:200,000 (Lehmann-Horn et al., 2004).
Sixteen mutations of the Nav1.4 channel have been found
to cause PMC in humans: L266V, A1152D, A1156T, V1293I,
G1306E, T1313M/A, M1360V, M1370V, L1433R, R1448C/H/P/S,
G1456E, and F1705I (McClatchey et al., 1992; Ptácek et al., 1992;
Lerche et al., 1993, 1996; Chahine et al., 1994; Yang et al., 1994;
Mitrovic et al., 1995; Wagner et al., 1997; Featherstone et al.,
1998; Green et al., 1998; Bendahhou et al., 1999a; Hayward et al.,
1999; Sasaki et al., 1999; Okuda et al., 2001; Wu et al., 2001, 2005;
Bouhours et al., 2004, 2005; Groome et al., 2005; Gay et al., 2008).
However, Nav1.4 mutations A1156T and M1360V have been clas-
siﬁed as both PMC and HyperPP. There are many similarities in
electrophysiological properties and clinical observations between
PMC and HyperPP. This led to a hypothesis that they are allelic
disorders, supported by genetic linkage of this disease locus to
the Nav1.4 channel gene on chromosome 17 (Fontaine et al.,
1990; Ptácek et al., 1991). Most of the PMC mutations are located
either on the inactivation particle (IFM; isoleucine, phenylalanine,
methionine) between domains III and IV, or on domain IV itself
at the S4 voltage sensor (Yang et al., 1994; Fleischhauer et al., 1998;
Bouhours et al., 2004).
Functional expression revealed that in most cases, PMC muta-
tions cause a decreased rate of channel inactivation and increased
rate of recovery from inactivation andothermutations cause chan-
nel deactivation to be slowed (Chahine et al., 1994;Goldman,1999;
Jurkat-Rott et al., 2010). The functional effects of PMC seem to
be more severe than those of PAM in that the time constant of
fast inactivation is greater due to increased channel activity. This
may lead to the clinical state of weakness of paralysis more efﬁ-
ciently than with PAM by depolarizing the resting potential and
inactivating Na+ channels.
SEVERE NEONATAL EPISODIC LARYNGOSPASM
Recently a novel Nav1.4 myotonia mutation was identiﬁed causing
severe neonatal episodic laryngospasm (SNEL) found to be lethal
in newborns (Lion-Francois et al., 2010). These newborns pre-
sented with episodic apneas and apparent life threatening events
that includedmyotonia of the laryngealmuscles preventing proper
ventilation.One infantwhowas not treated in timewith either car-
bamazepine or mexiletine died due to respiratory arrest during an
apneic episode. A de novo A799S missense mutation of the Nav1.4
channel was found in this patient (Lion-Francois et al., 2010;
Simkin et al., 2011). This mutation is located on the S6 transmem-
brane segment of domain II and results in such a severe phenotype
by shifting the steady state of activation in a hyperpolarizing direc-
tion, slowing the kinetics of fast inactivation and deactivation, and
dramatically increasing channel open probability (Simkin et al.,
2011).
Na+ channel mutations have already been described in
neonates (Tsujino et al., 2003; Gay et al., 2008). These patients had
hypotonia and were harboring mutations I693I and N1297K. In
addition to the myotonic events, these patients experienced mus-
cle weakness as well. Although muscle weakness can be triggered
in patients with Na+ channel myotonia, this clinical feature has
not been observed in patients carrying the A799S mutation, mak-
ing SNEL a distinct form of Na+ channel myotonia in newborn
babies.
PERIODIC PARALYSIS
Periodic paralysis can be caused by mutations of the Nav1.4
sodium channel which decrease its function, the L-type calcium
channel (DHPR), and the inwardly rectifying Kir2.1 channel by
inhibiting its function in Andersen’s syndrome. In some cases
of periodic paralysis, serum potassium levels are affected caus-
ing HyperPP, HypoPP, or normokalemic (where K+ levels remain
normal) thus periodic paralysis is deﬁned in terms of serum K+
levels.
HYPERKALEMIC PERIODIC PARALYSIS
Hyperkalemic periodic paralysis has been found in patients with
sodium channel mutations that cause attacks of ﬂaccid limb paral-
ysis or weakness of the eye or throat muscles. HyperPP patients
present with increased serum K+ levels during the episodes of
weakness. The triggers of HyperPP include K+ ingestion, rest after
exercise as well as cold temperatures, emotional stress, and fasting.
HyperPP and PMC have overlapping symptoms because between
episodes of periodic paralysis, HyperPP patients can experience a
mild form of myotonia, which may be more pronounced before
a paralytic attack. Also patients (which do not experience mild
myotonia episodes between paralytic attacks) may be more prone
to develop chronic progressivemyopathy duringmidlifewhenpar-
alytic attacks become more rare. Patients are usually diagnosed in
the ﬁrst decade of life and paralysis attacks increase in frequency
and severity during puberty but begin to decrease after approx-
imately 40 years of age. However, older individuals may develop
permanent weakness related to the frequency and severity of prior
attacks (Bradley et al., 1990; Ptácek et al., 1993a; Jurkat-Rott and
Lehmann-Horn, 2007b). During a paralytic attack, patients may
also experience respiratory insufﬁciency which could lead to death
if not treated immediately. Attacks can last up to an hour and dis-
appear as serum K+ levels decrease due to elimination by the
kidney and reuptake by skeletal muscle cells. However, after an
attack, as serum K+ levels drop, patients can become hypokalemic
leading to misdiagnoses (Plassart et al., 1994; Jurkat-Rott and
Lehmann-Horn, 2007b). Therefore, diagnoses are mostly based
on the patient response to K+ rather than the level of K+ during
an attack.
Several Nav1.4 mutations lead to HyperPP including L689I,
I693T, T704M, A1156T, M1360V, I1490L, M1493I, I1495F, and
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M1592V (McClatchey et al., 1992; Cannon and Strittmatter, 1993;
Cummins et al., 1993; Yang et al., 1994; Wagner et al., 1997;
Plassart-Schiess et al., 1998; Bendahhou et al., 1999b, 2000, 2002;
Hayward et al., 1999; Rojas et al., 1999). Mutations T704M and
M1592V account for themajority of HyperPP cases (Venance et al.,
2006). Most HyperPP mutations are located at the intracellular
loop between transmembrane segments S4 and S5 of domains
II and III or in the transmembrane segment S5 of domain IV.
These areas (at least in domains III and IV) are thought to form
a three-dimensional docking site for the fast inactivation particle.
Structural malformations in those areas may reduce the afﬁnity
of the IFM particle to this docking site reducing fast inactivation
of the Nav1.4 channel. Sodium channels typically open for several
milliseconds, but HyperPP mutations cause the Nav1.4 channel to
allow sodium current to ﬂow even after tens of milliseconds (Can-
non and Strittmatter, 1993). In the case of HyperPP, there is a per-
sistent inward sodium current and sustained depolarization which
leads to electrical inexcitability and muscle weakness (Lehmann-
Horn et al., 1987). Also in excised ﬁbers from patients there is
an accumulation of intracellular Na+ consistent with increased
inward sodium current (Weber et al., 2006). It is suggested that
persistent Na+ conductance leads to membrane depolarization
which drives K+ out of the cell into the extracellular space caus-
ing severe hyperkalemia and further depolarization of the muscle
ﬁbers and Na+ channel slow inactivation (Cannon et al., 1993;
Cummins and Bendahhou, 2009). Indeed, it has been found that
with HyperPP mutations L689I, I693T, T704M, and M1592V, the
slow inactivation process (a process that modulates the availability
of the channels) is impaired preventing the muscle from recover-
ing after muscle contraction and subsequently causing paralysis,
while in PMC the muscle is able to recover quicker (Cummins
and Sigworth, 1996; Plassart-Schiess et al., 1998; Bendahhou et al.,
1999b, 2002; Hayward et al., 1999; Cummins and Bendahhou,
2009; Platt and Griggs, 2009). Although, persistent current may
underlay periodic paralysis and myotonia, other mechanisms have
also been proposed. Some HyperPP mutations also shift the volt-
age dependence of activation in the negative direction which
shifts the activation threshold and allows channels to open sooner
(Cummins et al., 1993;Yang et al., 1994). This negative shift in acti-
vation leads to the rise of persistent currents that occur at voltage
ranges between activation and fast inactivation or window cur-
rents (Cummins et al., 1993; Yang et al., 1994; Bendahhou et al.,
1999b; Rojas et al., 1999). There are two mutations A1156T and
M1360V that are associated with both HyperPP and PMC, and
present with mixed phenotypes (Yang et al., 1994; Wagner et al.,
1997). Neither slow inactivation nor activation is affected with
these mutations, perhaps owing to the mixed clinical phenotype.
HYPOKALEMIC PERIODIC PARALYSIS
Hypokalemic periodic paralysis can be caused by mutations of the
Nav1.4 channel or the skeletal muscle calcium channel Cav1.1, or
the inward rectiﬁer potassium channel Kir2.1. HypoPP caused by
Ca2+ channel mutations is referred to as HypoPP1 while HypoPP
caused by Na+ channel mutations is referred to as HypoPP2
(Jurkat-Rott et al., 1994, 2000; Ptácek et al., 1994a; Sternberg
et al., 2001; Fontaine et al., 2007). The major differences between
HypoPP1 and HypoPP2 are that HypoPP1 has an earlier onset,
HypoPP2 presents with myalgias and can be aggravated by aceta-
zolamide (a carbonic anhydrase inhibitor typically used to treat
periodic paralysis), and in muscle biopsies there is a predomi-
nance of tubular aggregates in HypoPP2 and vacuoles in HypoPP1
(Fontaine et al., 2007; Platt and Griggs, 2009). HypoPP is charac-
terized by reversible attacks of muscle weakness with decreased
serum K+ levels. During HypoPP attacks, patients can lose their
muscle strength and reﬂexes and have subjective sensory symp-
toms. These attacks of weakness or paralysis are triggered by rest
after strenuous exercise, ingestion of carbohydrates exposure to
cold, or corticosteroid intake (Bendahhou et al., 2007). There is
no evidence in electromyographic studies that HypoPP patients
have any form of myotonia with the exception of eyelid myotonia
which can sometimes even be present between attacks (Ptácek and
Griggs, 1996). Attacks can last several hours or even days, unlike in
HyperPP,and aremore severe innature. Patients are usually at their
weakest during the later hours of the night and in the morning and
progressively get stronger as the day goes by. Once an attack has
resolved, patients appear completely normal. As patients get older,
attack frequency decreases but some develop progressive persis-
tent weakness in the form of proximal myopathy and can progress
to debilitating weakness (to the point of wheelchair conﬁnement)
especially those who were untreated throughout previous attacks.
Muscle biopsies from HypoPP patients reveal abnormal vacuoles
resulting from SR dilatation (possibly as a result of osmotic ﬂuxes)
or atrophic changes even during attack free intervals. However,
blood studies are unremarkable in these intervals.
A number of Nav1.4mutations resulting inHypoPP2 have been
found including inhumans:R222W,R669H,R672H/G/S,R1129Q,
R1132Q, R1135H, and P1158S (Struyk et al., 2000; Bendahhou
et al., 2001; Kuzmenkin et al., 2002; Sugiura et al., 2003; Carle
et al., 2006; Matthews et al., 2009; Hong et al., 2010). All Na+
or Ca2+ channel HypoPP mutations, are located on the voltage
sensors of these two channels. Sodium channel HypoPP muta-
tions are located primarily on the S4 voltage sensors of domains II
and III where they neutralize positively charged residues hinder-
ing proper voltage sensor function (Kontis et al., 1997; Kuhn and
Greeff, 1999; Matthews et al., 2009; Ruff, 2010). HypoPP Nav1.4
mutations (unlike other Nav1.4 mutations which cause a gain-
of-function by enhancing activation or impairing inactivation)
cause a channel loss of function by enhancing channel inactivation
which, can be achieved by enhancing fast inactivation, slow inacti-
vation or both reducing the availability of these sodium channels
(Jurkat-Rott et al., 2000;Ruff andCannon,2000; Struyk et al., 2000;
Bendahhou et al., 2001; Kuzmenkin et al., 2002). At normal mus-
cle resting membrane potentials (RMP), about 70% of the Nav1.4
channels are available for activation which is enough to generate
an AP. However, in HypoPP there is a signiﬁcantly depolarized
RMP which causes more Nav1.4 channels to enter the inactive and
unavailable state for AP generation, while muscle is contracting,
producingweakness.OtherHypoPPNav1.4mutations allow fewer
channels to enter the slow inactivation state when they need to rest
while muscle is active which prevents the turnover from inactive to
active channels to happen as needed for the muscle and thus more
Na+ channels enter the inactive state subsequently causing paraly-
sis. Nevertheless, this hypothesis of channel down regulation does
not seem to explain the paradoxical sarcolemmal depolarization
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with hypokalemia or paralysis induced by insulin and glucose
during HypoPP attacks (Tricarico et al., 1998; Ruff, 1999).
Recent studies propose that the depolarization seen with some
HypoPP mutations can be due to a cationic leak through the volt-
age sensor created by the mutations called the gating pore current
(channel up-regulation) which may cause a cellular pH imbal-
ance due to proton movement into the ﬁbers (Kuzmenkin et al.,
2002; Carle et al., 2006; Sokolov et al., 2007; Struyk and Cannon,
2007; Struyk et al., 2008). This gating pore is distinct from themain
sodium ionpore between segments S5 andS6 and is suggested tobe
formed by segments S1–S4 in each domain (making up four possi-
ble gating pores) perhaps by the mutation of the S4 segment (Yang
et al., 1997; Sato et al., 2001; Long et al., 2005; Sokolov et al., 2005;
Tombola et al., 2005). This gating current is a hyperpolarization
activated current of monovalent cations which counteracts the K+
current and depolarizes the RMP thus it would explain why mus-
cle ﬁbers are depolarized during hypokalemia (Jurkat-Rott and
Lehmann-Horn, 2007a; Jurkat-Rott et al., 2009). It has been sug-
gested that the gating pore may lower the intracellular pH leading
to (i) intracellularNa+ ion accumulation through the activation of
transporters such as the Na+/H+ exchanger, and/or (ii) the inhi-
bition of the inwardly rectifying K+ channels (see Matthews and
Hanna, 2010). However, this has not been sufﬁciently elucidated
because studies reporting on the gating currents corresponding
to several HypoPP mutations were conducted in Xenopus oocytes
only and have not been reproduced in mammalian cells (Sokolov
et al., 2007; Struyk and Cannon, 2007).
CONGENITAL MYASTHENIC SYNDROME
Myasthenic syndrome (CMS) is a disorderwith defective transmis-
sion of neuromuscular excitation resulting in muscle fatigue from
defects in presynaptic, synaptic, or postsynaptic proteins (Engel
et al., 2003). Patients experience fatigable generalized weakness
and recurrent attacks of respiratory and bulbar paralysis begin-
ning at birth. CMS can be caused by several types of defects. In one
case, nerve stimulation at physiological rates rapidly decreased the
compoundmuscleAPs but no abnormalities inRMPevokedquan-
tal release synaptic potentials, AChR channel kinetics, or endplate
ultrastructure was found. However, endplate potentials depolariz-
ing the resting potential to −40mV failed to excite APs (Tsujino
et al., 2003).
In this case, a Nav1.4 channel mutation (V1442E) was found
located at the extracellular linker between segments S3 and S4
of domain IV (Tsujino et al., 2003). Respiratory paralysis is not a
common symptomof Nav1.4mutation defects despite the fact that
Nav1.4 is the predominant sodium channel in respiratory muscles.
However, the CMS patient with the V1442E mutation did exhibit
respiratory paralysis as well as paralysis of other muscles such as
the bulbar muscles, limiting speech, and swallowing. This patient
had also been on an apnea monitor since infancy and received
ventilatory support during apneic attacks. In her early 1920s, the
patient had limited ocular ductions, and weakness throughout
her body worsened by activity. The V1442E mutation revealed an
enhancement of fast inactivation even at hyperpolarized potentials
and the availability of sodium channels was signiﬁcantly reduced,
even compared to HypoPP mutations, causing muscle AP failure
even though the RMP was normal.
TREATMENTS FOR SKELETAL MUSCLE SODIUM CHANNEL
MYOTONIAS AND PERIODIC PARALYZES
MYOTONIA
Treatment for myotonia is focused on reducing the involuntary
AP bursts without blocking the voluntary high-frequency mus-
cle stimulation. Although, it is important that PAM and PMC
patients modify their lifestyle to avoid the triggers of their diseases
such as potassium ingestion or cold temperatures, drug thera-
pies are commonly used to relieve and prevent muscle stiffness
(Table 2).
For PMC and PAM patients, anticonvulsants (phenytoin and
carbamazepine), anti-arrhythmics of the class IB (mexiletine and
tocainide), class IC (ﬂecainide and propafenone), and local anes-
thetics have been shown to have some efﬁcacy relieving stiffness
in PAM and preventing stiffness and weakness from occurring
in PMC (Trip et al., 2006; Alfonsi et al., 2007). Agents such
as mexiletine and ﬂecainide (orally absorbed methylated lido-
caine derivatives) prevent repetitive AP ﬁring and myotonia by
reversibly blocking sodium channels (Wang et al., 2004; De Bel-
lis et al., 2006). This therapeutic effect enhances sodium channel
inactivation and shifts the voltage dependence of steady state
inactivation in a hyperpolarizing direction and slows the recov-
ery from inactivation. In most cases, Nav1.4 mutations increased
mexiletine sensitivity however, this was found to be dependent on
the Nav1.4 mutation as in some cases mexiletine sensitivity was
reduced contributing to the heterogeneity of clinical symptoms
observed with mexiletine treatment (Fan et al., 1996; Feather-
stone et al., 1998; Takahashi and Cannon, 2001; Desaphy et al.,
2003).
Since PMC patients present with severe myotonia that over-
shadows their attacks of weakness most of these patients rarely
require medications for weakness. However, sometimes diuretic
carbonic anhydrase inhibitor medications such as acetazolamide
and hydrochlorothiazide can be given to reduce serumK+ levels or
Table 2 | Medication in the different forms of Na channel myotonia and
paralysis.
Disorders Therapies
PMC Anticonvulsants (phenytoin and carbamazepine)
Anti-arrhythmics of the class IB (mexiletine and tocainide)
Anti-arrhythmics class IC (ﬂecainide and propafenone)
Local anesthetics (acetazolamide and hydrochlorothiazide)
PAM Anticonvulsants (phenytoin and carbamazepine)
Anti-arrhythmics of the class IB (mexiletine and tocainide)
Anti-arrhythmics class IC (ﬂecainide and propafenone)
Local anesthetics
HyperPP β-adrenergic agonists such as (salbutamol used as an
inhalant)
Glucose/insulin therapy
Diuretic carbonic anhydrase inhibitors (acetazolamide and
dichlorphenamide and thiazides)
HypoPP Oral potassium
Acetazolamide or dichlorphenamide, triamterene,
aldosterone antagonists
Potassium-sparing diuretics
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lower the pH and decrease the frequency and severity of paralytic
events (Rudel et al., 1980; Ricker et al., 1983; Ptácek et al., 1993b;
Ptácek and Griggs, 1996).
PERIODIC PARALYSIS
Patients with HyperPP often ﬁnd that reducing their carbohy-
drate intake and avoiding strenuous exercise and cold improves
their condition. Other treatments include β-adrenergic agonists
such as salbutamol used as an inhalant on patients without
cardiac arrhythmia or glucose/insulin therapy (Hanna et al.,
1998). Diuretic carbonic anhydrase inhibitors (acetazolamide and
dichlorphenamide) and thiazides seem to be the most effective
in HyperPP (Sansone et al., 2008). Treatments that enhance slow
inactivation of sodium channels or shift the voltage dependence
of activation may be more effective in treating some HyperPP
patients.
Treatment of HypoPP is better achieved by administrating oral
potassium and by avoidance of carbohydrates and sodium in the
diet. Increasing K+ levels usually helps to reduce the paradoxi-
cal membrane depolarization and shifts the resting potential to
more normal hyperpolarized voltages. Administration of acetazo-
lamide or dichlorphenamide has also proven to be useful, how-
ever in some cases these agents can exacerbate symptoms and
triamterene (kidney sodium channel blocker used as a potassium-
sparing diuretic) is used instead (Torres et al., 1981; Tawil et al.,
2000; Sternberg et al., 2001; Venance et al., 2004). These car-
bonic anhydrase inhibitors also lower the intracellular sodium
levels in addition to repolarizing the RMP (perhaps by open-
ing calcium activated K+ channels; Tricarico et al., 1999). Other
aldosterone antagonists and potassium-sparing diuretics are also
used.
CONCLUSION
Skeletal muscle sodium channel disorders show signiﬁcant intra
and interfamilial phenotypical variability as well as variability in
the functional electrophysiological properties of the Nav1.4 chan-
nel. It remains difﬁcult to properly identify, classify, and treat
myotonia and periodic paralysis patients due to an insufﬁcient
understanding of the mechanism by which these mutations bring
about such variable phenotypes. Nav1.4 channel gating defects to
produce gain-of-function which slows the rate of inactivation and
or deactivation typically cause myotonia while Nav1.4 mutations
that negatively shift the voltage dependence of activation typically
cause HyperPP. Mutations that down-regulate Nav1.4 channel
function by enhancing slow inactivation or the newly suggested
mechanism of increased gating pore currents which depolarize
muscle ﬁbers in the presence of low extracellular K+ concentra-
tions result in HypoPP. If gating pore currents do indeed underlie
the abnormal depolarization associated with HypoPP, the “gating
pore” may represent a novel therapeutic target for treating these
patients. Nevertheless, functional studies may not lead to a full
understanding of these diseases and careful analysis of clinical phe-
notypes, clinical trials, and genetic screening are clearly still lacking
and needed. Understanding these different factors which underlie
skeletalmuscle sodiumchannel disordersmay help to improve and
develop new strategies of therapeutic treatment for these patients
as well as treatments of related disorders of excitability.
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